Dr Reddys Laboratories (RDY) EPS (Basic) (2012 - 2026)

Dr Reddys Laboratories' EPS (Basic) history runs 15 years deep, the most recent figure standing at $17.21 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 10.05% year-over-year to $17.21; the TTM figure through Mar 2026 stood at $1097.0 (down 28.6% YoY), while the FY2026 annual figure was $0.55, down 30.38% from the prior year.
• EPS (Basic) was $17.21 for Q1 2026 at Dr Reddys Laboratories, down from $247.76 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $832.54 in Q2 2024 to a low of $0.0 in Q3 2022.
• Historically, EPS (Basic) has averaged $209.0 across 5 years, with a median of $114.88 in 2023.
• The sharpest annual moves came in 2022 and 2023: EPS (Basic) slumped 100.0% in 2022, then soared 97632394.52% in 2023.
• A 5-year view of EPS (Basic) shows it stood at $0.55 in 2022, then surged by 49131.01% to $269.16 in 2023, then climbed by 7.71% to $289.91 in 2024, then fell by 14.54% to $247.76 in 2025, then plunged by 93.05% to $17.21 in 2026.
• The last three EPS (Basic) figures came in at $17.21 (Q1 2026), $247.76 (Q4 2025), and $832.04 (Q2 2025), per Business Quant data.